AMENDMENTS TO THE CLAIMS

1. (Original) A compound according to formula I:



,

wherein

R^1 is selected from the group consisting of hydroxy, halo, nitro, C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{1-6}alkyl, OC_{1-6}alkyl, C_{2-6}alkenyl, OC_{2-6}alkenyl, C_{2-6}alkynyl, OC_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, OC_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl, OC_{0-6}alkylaryl, CHO, $(CO)R^5$, $O(CO)R^5$, $O(CO)OR^5$, $O(CN)OR^5$, C_{1-6}alkylOR^5, OC_{2-6}alkylOR^5, C_{1-6}alkyl$(CO)R^5$, OC_{1-6}alkyl$(CO)R^5$, C_{0-6}alkylCO_2R^5, OC_{1-6}alkylCO_2R^5, C_{0-6}alkylcyano, OC_{2-6}alkylcyano, C_{0-6}alkylNR^5R^6, OC_{2-6}alkylNR^5R^6, C_{1-6}alkyl$(CO)NR^5R^6$, OC_{1-6}alkyl$(CO)NR^5R^6$, C_{0-6}alkyl$NR^5(CO)R^6$, OC_{2-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)NR^5R^6$, C_{0-6}alkylSR^5, OC_{2-6}alkylSR^5, C_{0-6}alkyl$(SO)R^5$, OC_{2-6}alkyl$(SO)R^5$, C_{0-6}alkylSO_2R^5, OC_{2-6}alkylSO_2R^5, C_{0-6}alkyl$(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)NR^5R^6$,C_{0-6}alkyl$NR^5(SO_2)R^6$, OC_{2-6}alkyl$NR^5(SO_2)R^6$, C_{0-6}alkyl$NR^5(SO_2)NR^5R^6$, OC_{2-6}alkyl$NR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6, C_{0-6}alkyl$NR^5(CO)OR^6$, OC_{2-6}alkyl$NR^5(CO)OR^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R^2 is selected from the group consisting of hydrogen, hydroxy, halo, nitro, C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{1-6}alkyl, OC_{1-6}alkyl, C_{2-6}alkenyl, OC_{2-6}alkenyl, C_{2-6}alkynyl, OC_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, OC_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl, OC_{0-6}alkylaryl, CHO, $(CO)R^5$,

$O(CO)R^5$, $O(CO)OR^5$, $O(CN)OR^5$, $C_{1-6}alkylOR^5$, $OC_{2-6}alkylOR^5$, $C_{1-6}alkyl(CO)R^5$, $OC_{1-6}alkyl(CO)R^5$, $C_{0-6}alkylCO_2R^5$, $OC_{1-6}alkylCO_2R^5$, $C_{0-6}alkylcyano$, $OC_{2-6}alkylcyano$, $C_{0-6}alkylNR^5R^6$, $OC_{2-6}alkylNR^5R^6$, $C_{1-6}alkyl(CO)NR^5R^6$, $OC_{1-6}alkyl(CO)NR^5R^6$, $C_{0-6}alkylNR^5(CO)R^6$, $OC_{2-6}alkylNR^5(CO)R^6$, $C_{0-6}alkylNR^5(CO)NR^5R^6$, $C_{0-6}alkylSR^5$, $OC_{2-6}alkylSR^5$, $C_{0-6}alkyl(SO)R^5$, $OC_{2-6}alkyl(SO)R^5$, $C_{0-6}alkylSO_2R^5$, $OC_{2-6}alkylSO_2R^5$, $C_{0-6}alkyl(SO_2)NR^5R^6$, $OC_{2-6}alkyl(SO_2)NR^5R^6$,$C_{0-6}alkylNR^5(SO_2)R^6$, $OC_{2-6}alkylNR^5(SO_2)R^6$, $C_{0-6}alkylNR^5(SO_2)NR^5R^6$, $OC_{2-6}alkylNR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6, $C_{0-6}alkylNR^5(CO)OR^6$, $OC_{2-6}alkylNR^5(CO)OR^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R^3 is selected from the group consisting of:

H, $C(O)OC_{1-6}alkylhalo$, $C(O)OC_{1-6}alkyl$, $C(O)OC_{2-6}alkenyl$, $C(O)OC_{2-6}alkynyl$, $C(O)OC_{0-6}alkylC_{3-6}cycloalkyl$, $C(O)OC_{0-6}alkylaryl$, $C(O)OC_{1-6}alkylOR^5$, $C(O)OC_{1-6}alkyl(CO)R^5$, $C(O)OC_{1-6}alkylCO_2R^5$, $C(O)OC_{1-6}alkylcyano$, $C(O)OC_{0-6}alkylNR^5R^6$, $C(O)OC_{1-6}alkyl(CO)NR^5R^6$, $C(O)OC_{2-6}alkylNR^5(CO)R^6$, $C(O)C_{1-6}alkylNR^5(CO)NR^5R^6$, $C(O)OC_{2-6}alkylSR^5$, $C(O)OC_{1-6}alkyl(SO)R^5$, $C(O)OC_{1-6}alkylSO_2R^5$, $C(O)OC_{1-6}alkyl(SO_2)NR^5R^6$, $C(O)OC_{1-6}alkylNR^5(SO_2)R^6$, $C(O)OC_{2-6}alkylNR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $C(O)OC_{1-6}alkylNR^5(CO)OR^6$, $C(S)OC_{1-6}alkylhalo$, $C(S)OC_{1-6}alkyl$, $C(S)OC_{2-6}alkenyl$, $C(S)OC_{2-6}alkynyl$, $C(S)OC_{0-6}alkylC_{3-6}cycloalkyl$, $C(S)OC_{0-6}alkylaryl$, $C(S)OC_{1-6}alkylOR^5$, $C(S)OC_{1-6}alkyl(CO)R^5$, $C(S)OC_{1-6}alkylCO_2R^5$, $C(S)OC_{1-6}alkylcyano$, $C(S)OC_{0-6}alkylNR^5R^6$, $C(S)OC_{1-6}alkyl(CO)NR^5R^6$, $C(S)OC_{2-6}alkylNR^5(CO)R^6$, $C(S)C_{1-6}alkylNR^5(CO)NR^5R^6$, $C(S)OC_{2-6}alkylSR^5$, $C(S)OC_{1-6}alkyl(SO)R^5$, $C(S)OC_{1-6}alkylSO_2R^5$, $C(S)OC_{1-6}alkyl(SO_2)NR^5R^6$, $C(S)OC_{1-}$

$_{6}$alkylNR^{5}(SO$_2$)R^{6}, C(S)OC$_{2\text{-}6}$alkylNR^{5}(SO$_2$)NR^{5}R^{6}, (CO)NR^{5}R^{6}, and C(S)OC$_{1\text{-}}$ $_{6}$alkylNR^{5}(CO)OR^{6};

R^{4} is selected from the group consisting of hydroxy, halo, nitro, C$_{1\text{-}6}$alkylhalo, OC$_{1\text{-}6}$alkylhalo, C$_{1\text{-}6}$alkyl, OC$_{1\text{-}6}$alkyl, C$_{2\text{-}6}$alkenyl, OC$_{2\text{-}6}$alkenyl, C$_{2\text{-}6}$alkynyl, OC$_{2\text{-}6}$alkynyl, C$_{0\text{-}6}$alkylC$_{3\text{-}}$ $_{6}$cycloalkyl, OC$_{0\text{-}6}$alkylC$_{3\text{-}6}$cycloalkyl, C$_{0\text{-}6}$alkylaryl, OC$_{0\text{-}6}$alkylaryl, CHO, (CO)R^{5}, O(CO)R^{5}, O(CO)OR^{5}, O(CN)OR^{5}, C$_{1\text{-}6}$alkylOR^{5}, OC$_{2\text{-}6}$alkylOR^{5}, C$_{1\text{-}6}$alkyl(CO)R^{5}, OC$_{1\text{-}6}$alkyl(CO)R^{5}, C$_{0\text{-}}$ $_{6}$alkylCO$_2$R^{5}, OC$_{1\text{-}6}$alkylCO$_2$R^{5}, C$_{0\text{-}6}$alkylcyano, OC$_{2\text{-}6}$alkylcyano, C$_{0\text{-}6}$alkylNR^{5}R^{6}, OC$_{2\text{-}}$ $_{6}$alkylNR^{5}R^{6}, C$_{1\text{-}6}$alkyl(CO)NR^{5}R^{6}, OC$_{1\text{-}6}$alkyl(CO)NR^{5}R^{6}, C$_{0\text{-}6}$alkylNR^{5}(CO)R^{6}, OC$_{2\text{-}}$ $_{6}$alkylNR^{5}(CO)R^{6}, C$_{0\text{-}6}$alkylNR^{5}(CO)NR^{5}R^{6}, C$_{0\text{-}6}$alkylSR^{5}, OC$_{2\text{-}6}$alkylSR^{5}, C$_{0\text{-}6}$alkyl(SO)R^{5}, OC$_{2\text{-}6}$alkyl(SO)R^{5}, C$_{0\text{-}6}$alkylSO$_2$R^{5}, OC$_{2\text{-}6}$alkylSO$_2$R^{5}, C$_{0\text{-}6}$alkyl(SO$_2$)NR^{5}R^{6}, OC$_{2\text{-}}$ $_{6}$alkyl(SO$_2$)NR^{5}R^{6},C$_{0\text{-}6}$alkylNR^{5}(SO$_2$)R^{6}, OC$_{2\text{-}6}$alkylNR^{5}(SO$_2$)R^{6}, C$_{0\text{-}6}$alkylNR^{5}(SO$_2$)NR^{5}R^{6}, OC$_{2\text{-}6}$alkylNR^{5}(SO$_2$)NR^{5}R^{6}, (CO)NR^{5}R^{6}, O(CO)NR^{5}R^{6}, NR^{5}OR^{6}, C$_{0\text{-}6}$alkylNR^{5}(CO)OR^{6}, OC$_{2\text{-}}$ $_{6}$alkylNR^{5}(CO)OR^{6}, =NR^{5}, =NOR^{5}, =O, =S, SO$_3$R^{5} and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

M is selected from the group consisting of =O, (CR^{5}R^{6})$_m$ and (CR^{5}R^{6})$_m$C(O);

R^{5} and R^{6} are independently selected from the group consisting of hydrogen, C$_{1\text{-}6}$alkyl, OC$_{1\text{-}}$ $_{6}$alkyl, C$_{3\text{-}7}$cycloalkyl, OC$_{3\text{-}7}$cycloalkyl, C$_{1\text{-}6}$alkylaryl, OC$_{1\text{-}6}$alkylaryl, aryl, and heteroaryl;

any C_{1-6}alkyl, aryl or heteroaryl defined under R^1, R^2, R^3, R^4, R^5 and R^6 may be substituted by one or more A;

A is selected from the group consisting of hydrogen, hydroxy, halo, nitro, oxo, C_{0-6}alkylcyano, C_{0-4}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{2-6}alkenyl, C_{0-3}alkylaryl, C_{0-6}alkylOR^5, OC_{2-6}alkylOR^5, C_{1-6}alkylSR^5, OC_{2-6}alkylSR^5, $(CO)R^5$, $O(CO)R^5$, OC_{2-6}alkylcyano, OC_{1-6}alkylCO_2R^5, $O(CO)OR^5$, OC_{1-6}alkyl$(CO)R^5$, C_{1-6}alkyl$(CO)R^5$, NR^5OR^6, C_{1-6}alkylNR^5R^6, OC_{2-6}alkylNR^5R^6, C_{0-6}alkyl$(CO)NR^5R^6$, OC_{1-6}alkyl$(CO)NR^5R^6$, OC_{2-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)NR^5R^6$, $O(CO)NR^5R^6$, C_{0-6}alkyl$(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)NR^5R^6$, C_{0-6}alkyl$NR^5(SO_2)R^6$, OC_{2-6}alkyl$NR^5(SO_2)R^6$, SO_3R^5, C_{1-6}alkyl$NR^5(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)R^5$, C_{0-6}alkyl$(SO_2)R^5$, C_{0-6}alkyl$(SO)R^5$, OC_{2-6}alkyl$(SO)R^5$ and a 5- or 6-membered ring containing one or more atoms independently selected from the group consisting of C, N, O and S;

m is 1, 2, or 3;

n is an integer between 0 and 8, inclusive; or

a pharmaceutically acceptable salt or hydrate thereof.

2. (Original) The compound according to claim 1, wherein n is 0.

3. (Original) The compound according to claim 2, wherein R^3 is selected from the group consisting of:

$C(O)OC_{1-6}alkylhalo$, $C(O)OC_{1-6}alkyl$, $C(O)OC_{2-6}alkenyl$, $C(O)OC_{2-6}alkynyl$, $C(O)OC_{0-6}alkylC_{3-6}cycloalkyl$, $C(O)OC_{0-6}alkylaryl$, $C(O)OC_{1-6}alkylOR^5$, $C(O)OC_{1-6}alkyl(CO)R^5$, $C(O)OC_{1-6}alkylCO_2R^5$, $C(O)OC_{1-6}alkylcyano$, $C(O)OC_{0-6}alkylNR^5R^6$, $C(O)OC_{1-6}alkyl(CO)NR^5R^6$, $C(O)OC_{2-6}alkylNR^5(CO)R^6$, $C(O)C_{1-6}alkylNR^5(CO)NR^5R^6$, $C(O)OC_{2-6}alkylSR^5$, $C(O)OC_{1-6}alkyl(SO)R^5$, $C(O)OC_{1-6}alkylSO_2R^5$, $C(O)OC_{1-6}alkyl(SO_2)NR^5R^6$, $C(O)OC_{1-6}alkylNR^5(SO_2)R^6$, $C(O)OC_{2-6}alkylNR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, and $C(O)OC_{1-6}alkylNR^5(CO)OR^6$.

4. (Original) The compound according to claim 3, wherein R^3 is selected from the group consisting of $C(O)OC_{1-6}alkyl$, $C(O)OC_{0-6}alkylaryl$, $C(O)OC_{1-6}alkylOR^5$, and $(CO)NR^5R^6$.

5. (Original) The compound according to claim 2, wherein R^2 is hydrogen or fluoro.

6. (Original) The compound according to claim 5, wherein M is CR^5R^6.

7. (Original) The compound according to claim 6, wherein R^6 in M is H.

8. (Original) The compound according to claim 7, wherein R^5 in M is selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{1-6}alkylaryl, aryl, and heteroaryl.

9. (Original) The compound according to claim 8, wherein R^5 is C_{1-6}alkyl.

10. (Original) The compound according to claim 8, wherein R^5 is C_{3-7}cycloalkyl.

11 (Original) The compound according to claim 8, wherein R^5 is heteroaryl.

12. (Original) The compound according to claim 11, wherein heteroaryl is selected from the group consisting of 2-, 3-, and 4-pyridyl; 2- and 3-thienyl; and 2- and 3-furanyl.

13. (Original) The compound according to claim 8, wherein R^5 is aryl.

14. (Original) The compound according to claim 13, wherein aryl is phenyl.

15. (Original) The compound according to claim 1, selected from the group consisting of:

4-[3-(3-Chloro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-(3-Phenyl-prop-2-ynyl)-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Cyano-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-(3-m-Tolyl-prop-2-ynyl)-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Methoxy-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(5-Cyano-2-fluoro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(2-Fluoro-5-methyl-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(5-Chloro-2-fluoro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-methyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-isopropyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[1-tert-Butyl-3-(3-chloro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-phenyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[1-(3-Chloro-phenylethynyl)-butyl]-piperazine-1-carboxylic acid ethyl ester,

4-[1-(3-Chloro-phenylethynyl)-3-methyl-butyl]-piperazine-1-carboxylic acid ethyl ester,

4-[1-Benzyloxymethyl-3-(3-chloro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-cyclopropyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[1-(3-Chloro-phenylethynyl)-pentyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-thiophen-2-yl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-thiophen-3-yl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-furan-2-yl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid tert-butyl ester,

1-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid isopropyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid propyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid isobutyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid butyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid 2,2-dimethyl-propyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid pentyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid 2-methoxy-ethyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid phenyl ester,

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid benzyl ester,

4-[3-(3-Chloro-phenyl)-1-pyridin-3-yl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-(2,4-difluoro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-(2-methoxy-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-(2-chloro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-o-tolyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-m-tolyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-(6-methoxy-pyridin-3-yl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

4-[3-(3-Chloro-phenyl)-1-(2-chloro-pyridin-3-yl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester,

Ethyl 4-[3-(5-chloro-2-fluorophenyl)-1-ethylprop-2-yn-1-yl]piperazine-1-carboxylate

Ethyl 4-[3-(3-chlorophenyl)-1-(5-methyl-2-furyl)prop-2-yn-1-yl]piperazine-1-carboxylate

Ethyl 4-{3-(3-chlorophenyl)-1-[5-(methoxycarbonyl)-2-furyl]prop-2-yn-1-yl}piperazine-1-carboxylate

2,2,2-Trifluoroethyl 4-[3-(3-chlorophenyl)-1-(2-furyl)prop-2-yn-1-yl]piperazine-1-carboxylate

Ethyl 4-{3-(3-chlorophenyl)-1-[5-(hydroxymethyl)-2-furyl]prop-2-yn-1-yl}piperazine-1-carboxylate

Ethyl (3S)-4-[(1R)-3-(3-chlorophenyl)-1-(2-furyl)prop-2-yn-1-yl]-3-methylpiperazine-1-carboxylate

Ethyl (3S)-4-[(1S)-3-(3-chlorophenyl)-1-(2-furyl)prop-2-yn-1-yl]-3-methylpiperazine-1-carboxylate

Ethyl (3R)-4-[(1S)-3-(3-chlorophenyl)-1-ethylprop-2-yn-1-yl]-3-methylpiperazine-1-carboxylate

Ethyl (3R)-4-[(1R)-3-(3-chlorophenyl)-1-(2-furyl)prop-2-yn-1-yl]-3-methylpiperazine-1-carboxylate

Ethyl (3R)-4-[(1R)-3-(3-chlorophenyl)-1-ethylprop-2-yn-1-yl]-3-methylpiperazine-1-carboxylate

Ethyl (3S)-4-[(1S)-3-(3-chlorophenyl)-1-ethylprop-2-yn-1-yl]-3-methylpiperazine-1-carboxylate

Ethyl (3S)-4-[(1R)-3-(3-chlorophenyl)-1-methylprop-2-yn-1-yl]-3-methylpiperazine-1-carboxylate

4-[3-(3-Chloro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid tert-butyl ester

4-[1-(Tert-Butoxycarbonylamino-methyl)-3-(3-chloro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester

4-[3-(3-Chloro-phenyl)-1-triisopropylsilyloxymethyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester

Ethyl 4-[3-(3-chlorophenyl)-1-(ethoxymethyl)prop-2-yn-1-yl]piperazine-1-carboxylate

4-[1-Aminomethyl)-3-(3-chloro-phenyl)-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester

4-[3-(3-Chloro-phenyl)-1-hydroxymethyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester

4-[3-(3-Chloro-phenyl)-1-methoxymethyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester

4-(3-Phenyl-propynoyl)-piperazine-1-carboxylic acid ethyl ester

Ethyl 4-[3-(3-Chloro-phenyl)-1,1-dimethyl-prop-2-ynyl]-piperazine-1-carboxylic acid ethyl ester

4-[3-(3-Chloro-phenyl)-1-ethyl-prop-2-ynyl]-piperazine-1-carboxylic acid methyl ester

4-[3-(3-Chloro-phenyl)-prop-2-ynyl]-piperazine-1-caroxylic acid 2-methoxy-ethyl ester, and

pharmaceutically acceptable salts or hydrates thereof.

16. (Original) A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 to 15, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

17. (CANCELLED)

18. (Currently Amended) The compound according to ~~any one of claims 1 to 15~~ claim 1, for use in therapy.

19. (Currently Amended) The compound according to ~~any one of claims 1 to 15~~ claim 1, for use in treatment of mGluR 5 mediated disorders.

20. (Currently Amended) Use of the compound according to ~~any one of claims 1 to 15~~ claim 1, in the manufacture of a medicament for the treatment of mGluR 5 mediated disorders.

21. (Currently Amended) A method of treatment of mGluR 5 mediated disorders, comprising administering to a mammal a therapeutically effective amount of the compound according to ~~any one of claims 1 to 15~~ claim 1.

22. (Original) The method according to claim 21, wherein the mammal is a human.

23. (Original) The method according to claim 21, wherein the disorders are neurological disorders.

24. (Original) The method according to claim 21, wherein the disorders are psychiatric disorders.

25. (Original) The method according to claim 21, wherein the disorders are chronic and acute pain disorders.

26. (Original) The method according to claim 21, wherein the disorders are gastrointestinal disorders.

27. (Original) A method for inhibiting activation of mGluR 5 receptors, comprising treating a cell containing said receptor with an effective amount of the compound according to claim 1.